Echocardiographic signs of right ventricle changes after Trastuzumab treatment in breast cancer patients with erb-2 overexpression

• Published in: Anadolu kardiyoloji dergisi : AKD 2015-02, Vol.15 (2), p.143-148
• Main Authors: Kılıçaslan, Barış, Özdoğan, Öner, Demir Pişkin, Gönül, Kahya Eren, Nihan, Dursun, Hüseyin
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Echocardiography; Female; Humans; Middle Aged; Original Investigation; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Trastuzumab - adverse effects; Trastuzumab - therapeutic use; Ventricular Dysfunction, Right - chemically induced; Ventricular Dysfunction, Right - diagnostic imaging
• ISSN: 1302-8723; 2149-2263; 2149-2271; 1308-0032
• DOI: 10.5152/akd.2014.5220

Left ventricular (LV) dysfunction after trastuzumab treatment in erb-2 breast cancer cases has been fully investigated. However, there is not enough data about the effect of trastuzumab treatment on right ventricular (RV) functions. This study is designed to evaluate the right heart changes by performing echocardiography after trastuzumab treatment in patients with erb-2 breast cancer. Forty-two consecutive breast cancer patients with erb-2 overexpression mean age 50.4 ± 11.6 years who were decided to receive trastuzumab treatment were enrolled. Echocardiographic examinations including 2-D, spectral, and tissue Doppler measurements were performed at the baseline (T1) and repeated after 6 months (T2). Tricuspid annular plane systolic excursion (TAPSE) was decreased, RV myocardial performance index (RVMPI) and tricuspid E/e' ratio was increased after trastuzumab treatment (1.84 vs. 2.14; p